Search Results - "van Egmond, H.M."

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy by Griffioen, Marieke, van Egmond, Esther H.M, Kester, Michel G.D, Willemze, Roel, Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M

“…Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands Correspondence: Marieke Griffioen, Dept. of Hematology, C2-R,…”
Get full text

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application by Griffioen, Marieke, van Egmond, H.M. Esther, Barnby-Porritt, Helen, van der Hoorn, Menno A.W.G, Hagedoorn, Renate S, Kester, Michel G.D, Schwabe, Nikolai, Willemze, Roel, Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M

“…1 Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands 2 ProImmune Ltd., The Magdalen Centre, Oxford Science Park,…”
Get full text

Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies by VAN LOENEN, Marleen M, DE BOER, Renate, HAGEDOORN, Renate S, VAN EGMOND, Esther H. M, FREDERIK FALKENBURG, J. H, HEEMSKERK, Mirjam H. M

“…To broaden the applicability of adoptive T-cell therapy for the treatment of hematologic malignancies, we aim to start a clinical trial using HA-1-TCR…”
Get full text

CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity by van der Heiden, P.L.J., van Egmond, H.M., Veld, S.A.J., van de Meent, M., Eefting, M., de Wreede, L.C., Halkes, C.J.M., Falkenburg, J.H.F., Marijt, W.A.F., Jedema, I.

“…Cytomegalovirus (CMV)-specific T-cells are crucial to prevent CMV disease. CMV seropositive recipients transplanted with stem cells from a CMV seronegative…”
Get full text

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II by van Balen, P., van Bergen, C.A.M., Jedema, I., van Luxemburg-Heijs, S.A.P., Harskamp, J.C., van Egmond, H.M., Veld, S.A.J., Griffioen, M., Marijt, W.A.F., Halkes, C.J.M., Falkenburg, J.H.F.

“…Abstract 4116 Donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) can mediate curative Graft-versus-Leukemia (GVL) reactivity…”
Get full text

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control by Halkes, C.J.M., Jedema, I, van Egmond, H.M., van der Fits, L, Falkenburg, J.H.F., Vermeer, MH

“…Abstract 2491 Alemtuzumab (ALT) is a monoclonal anti CD52 antibody used for the treatment of CD52 positive lymphoid malignancies and to deplete T cells in vivo…”
Get full text

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab by Halkes, C.J.M., Falkenburg, J.H.F., van Egmond, H.M., Wolbers, J. Olde, Starrenburg, C.W.J., van Balen, P., van de Meent, M., von dem Borne, P.A., Marijt, W.A.F., Veelken, J.H., Jedema, I

“…Abstract 1979 Control of replication of endogenous viruses like CMV and EBV is fully dependent on CMV or EBV specific T cells after allogeneic stem cell…”
Get full text

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II by van Balen, Peter, van Bergen, Cornelis A M, van Luxemburg-Heijs, Simone A P, de Klerk, Wendy, van Egmond, Esther H M, Veld, Sabrina A J, Halkes, Constantijn J M, Zwaginga, Jaap-Jan, Griffioen, Marieke, Jedema, Inge, Falkenburg, J H Frederik

“…Under non-inflammatory conditions HLA class II is predominantly expressed on hematopoietic cells. Therefore, donor CD4 T-cells after allogeneic stem cell…”
Get full text

Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft by Loeff, Floris C., van Egmond, Esther H.M., Moes, Dirk J.A.R., Wijnands, Charissa, Von Dem Borne, Peter A., Veelken, Hendrik, Falkenburg, J.H. Frederik, Jedema, Inge, Halkes, Constantijn J.M.

“…Administration of alemtuzumab (targeting the CD52 antigen) to the patient (in-vivo) or to the graft (in-vitro) before allogeneic stem cell transplantation…”
Get full text

T Cell Receptor Gene Transfer to Virus-Specific T Cells for Cellular Anti-Tumor Immunotherapy by Griffioen, Marieke, van Egmond, H.M. Esther, van der Hoorn, Menno A.W.G., Hagedoorn, Renate S., Kester, Michel, Willemze, Roelof, Falkenburg, J.H. Frederik, Heemskerk, Mirjam

“…Patients with relapsed hematological malignancies after allogeneic stem cell transplantation (alloSCT) can be successfully treated by donor lymphocyte…”
Get full text

Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins by Loeff, Floris C, van Egmond, Esther H.M., Wolbers, Judith Olde, Falkenburg, J.H. Frederik, Halkes, Constantijn J.M., Jedema, Inge

“…Membrane-bound complement regulatory proteins (mCRPs) are known to protect cells from bystander lysis and spontaneous activation of complement. In the case of…”
Get full text

Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression by Loeff, Floris C., Rijs, Kevin, Egmond, Esther H. M., Zoutman, Willem H., Qiao, Xiaohang, Kroes, Wilhelmina G. M., Veld, Sabrina A. J., Griffioen, Marieke, Vermeer, Maarten H., Neefjes, Jacques, Frederik Falkenburg, J. H., Halkes, Constantijn J. M., Jedema, Inge

“…Adult B‐lymphoblastic leukemia (B‐ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with…”
Get full text

Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion by Koster, Eva A.S., von dem Borne, Peter A., van Balen, Peter, van Egmond, Esther H.M., Marijt, Erik W.A., Veld, Sabrina A.J., Jedema, Inge, Snijders, Tjeerd J.F., van Lammeren, Daniëlle, Veelken, Hendrik, Falkenburg, J.H. Frederik, de Wreede, Liesbeth C., Halkes, Constantijn J.M.

“…•Effective donor lymphocyte infusion (DLI) after transplantation does not require graft-versus-host disease.•Competitive stem cell repopulation can suffice for…”
Get full text

Retroviral Gene Transfer of T Cell Receptors (TCR) Specific for Minor Histocompatibility Antigens to Virus-Specific T Cells as Cellular Immunotherapy of Patients with Relapsed Hematological Malignancies after Allogeneic Stem Cell Transplantation by Griffioen, Marieke, van Egmond, H.M. Esther, van der Hoorn, Menno A.W.G., Hagedoorn, Renate S., Kester, Michel, Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

“…Patients with hematological malignancies can be successfully treated by T cell-depleted allogeneic stem cell transplantation (alloSCT) followed by donor…”
Get full text

Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia by Kloosterboer, Freke M., van Luxemburg-Heijs, Simone A.P., van Soest, Ronald A., van Egmond, H.M. Esther, Willemze, Roel, Falkenburg, J.H. Frederik

“…T cells directed against hematopoietic-restricted minor histocompatibility antigens (mHags) may mediate graft-versus-leukemia (GVL) reactivity without…”
Get full text

Eradication of Recipient CMV Specific T Cells by Donor Lymphocyte Infusion Does Not Impair Protective Immunity In Patients Transplanted with a CMV Negative Donor Due to An Early Donor Derived Primary CMV Specific T Cell Response by van der Heiden, Pim L.J., Harskamp, Jessica C., van Egmond, Esther H.M., Deutz-Terlouw, Piëtte P., Falkenburg, J.H. Frederik, Marijt, Erik W.A.

“…Abstract 834 Previous studies have demonstrated that shortly after T cell depleted (TCD) allogeneic stem cell transplantation (alloSCT) CMV specific T cells in…”
Get full text

T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status by Harskamp, Jessica C., van der Heiden, Pim L.J., van Egmond, Esther H.M., Veld, Sabrina A.J., Vos, Hans L., Halkes, Constantijn J.M., Falkenburg, J.H. Frederik, Marijt, Erik W.A.

“…Abstract 1321 Following T cell depleted (TCD) allogeneic stem cell transplantation (alloSCT) more patients (pts) show mixed chimerism (MC) as compared to…”
Get full text

Rapid Re-expression of Retrovirally Introduced VersusEndogenous TCRs in Engineered T cells AfterAntigen-specific Stimulation by van Loenen, Marleen M., Hagedoorn, Renate S., de Boer, Renate, van Egmond, Esther H.M., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

Get full text

Myeloid Chimerism Reflects Engraftment of Donor Hematopoiesis, Whereas T Cell Chimerism Reflects Survival and Expansion of Donor and Recipient Residual Mature T Cells Early After T Cell Depleted Allogeneic Stem Cell Transplantation by Harskamp, Jessica C., van Egmond, Esther H.M., Vos, Hans L., Halkes, Stijn J.M., Willemze, Roel, Falkenburg, J.H. Frederik, Marijt, Erik W.A.

“…Abstract 4475 Allogeneic stem cell transplantation (alloSCT) is frequently complicated by life-threatening graft versus host disease (GVHD). Previous studies…”
Get full text

Physiological TCR Modulation after Antigen Specific Triggering of Introduced TCRs under Control of a Retroviral Promotor by van Loenen, Marleen M., Hagedoorn, Renate S., van Egmond, Esther H.M., Willemze, Roel, Falkenburg, J.H.Frederik, Heemskerk, Mirjam H.M.

“…TCR transfer to engineer tumor specific T cells may be an alternative strategy for adoptive immunotherapy. We have previously shown that TCR-transduced T cells…”
Get full text